Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson's Coronavirus Vaccine Won't Be in Clinical Trials Until November

By Brian Orelli, PhD - Mar 18, 2020 at 7:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Will slow but steady win the race?

The little guys are winning the race to develop the first vaccine against the SARS-CoV-2 coronavirus that causes COVID-19.

Moderna (MRNA -5.69%) started a phase 1 clinical trial for its coronavirus vaccine mRNA-1273 this week. Earlier this month, Inovio Pharmaceuticals (INO -5.63%) said it's finishing up preclinical testing of its INO-4800 vaccine and plans to start a clinical trial next month.

Big old Johnson & Johnson (JNJ 0.11%)? The healthcare conglomerate doesn't even have a candidate yet.

The company started working on a vaccine in January but only expects to have a candidate picked out by the end of this month, according to an interview with Johnson & Johnson's chief scientific officer, Paul Stoffels, on CNBC.

The different time frames for development likely have to do with the platforms the companies are using. Moderna uses mRNA -- the intermediary between DNA and the proteins they encode for -- that the patients' cells use to express the viral proteins needed to get an immune response. Inovio's platform uses DNA with the patients' cells doing both steps -- DNA to mRNA to protein -- to create the immune reaction.

To create their vaccines, Moderna and Inovio just needed the sequence of the virus and a good guess at which viral proteins are likely to have the best immune reaction. Work on previous coronaviruses, such as the one that causes Middle East respiratory syndrome (MERS), gave big clues as to which proteins would be most immunogenic.

Cartoon of a rabbit and a tortoise in a race

Image source: Getty Images.

Johnson & Johnson appears to be using a more traditional approach in which the virus is inactivated so it can't replicate but can still express viral proteins. The approach takes a little longer for both the development and manufacturing scale-up steps. On the plus side, Johnson & Johnson's slow-but-steady approach could create a vaccine with a better immune response.

We'll know sometime next year whether the rabbit or the tortoise won this race.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$167.76 (0.11%) $0.19
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$2.56 (-5.63%) $0.15
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$158.40 (-5.69%) $-9.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.